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ABSTRACT  
Background: Long-non-coding RNAs (lncRNAs), RNA molecules longer than 200 nucleotides, have been 
involved in several biological processes and in a growing number of diseases, controlling gene transcription, 
pre-mRNA processing, the transport of mature mRNAs to specific cellular compartments, the regulation of 
mRNA stability, protein translation and turnover. The fundamental role of lncRNAs in central nervous 
system (CNS) is becoming increasingly evident. LncRNAs are abundantly expressed in mammalian CNS in a 
specific spatio-temporal manner allowing a quick response to environmental/molecular changes. Methods: 
This article reviews the biology and mechanisms of action of lncRNAs underlying their potential role in CNS 
and in some neurodegenerative diseases. Results: an increasing number of studies report on lncRNAs 
involvement in different molecular mechanisms of gene expression modulation in CNS, from neural stem 
cell differentiation mainly by chromatin remodeling, to control of neuronal activities. More recently, 
lncRNAs have been implicated in neurodegenerative diseases, including Alzheimer’s Disease, where the 
role of BACE1-AS lncRNA has been widely defined. BACE1-AS levels are up-regulated in AD brains where 
BACE1-AS acts by stabilizing BACE1 mRNA thereby increasing BACE1 protein content and Aβ42 formation. 
In Frontotemporal dementia and Amyotrophic lateral sclerosis the lncRNAs NEAT1_2 and MALAT1 co-
localize at nuclear paraspeckles with TDP-43 and FUS proteins and their binding to TDP-43 is markedly 
increased in affected brains. In Parkinson’s Disease the lncRNA UCHL1-AS1 acts by directly promoting 
translation of UCHL1 protein leading to perturbation of the ubiquitin-proteasome system. Different 
lncRNAs, such as HTT-AS, BDNF-AS and HAR1, were found to be dysregulated in their expression also in 
Huntington’s Disease. In Fragile X syndrome (FXS) and Fragile X tremor/ataxia syndrome (FXTAS) patients, 
the presence of CGG repeats expansion alters the expression of the lncRNAs FMR1-AS1 and FMR6. 
Interestingly, they are expressed in peripheral blood leukocytes, suggesting these lncRNAs may represent 
biomarkers for FXS/FXTAS early detection and therapy. Finally, the identification of the antisense RNAs 
SCAANT1-AS and ATXN8OS in spinocerebellar ataxia 7 and 8, respectively, suggests that very different 
mechanisms of action driven by lncRNAs may trigger neurodegeneration in these disorders.  
The emerging role of lncRNAs in neurodegenerative diseases suggests that their dysregulation could trigger 
neuronal death via still unexplored RNA-based regulatory mechanisms which deserve further investigation. 
The evaluation of their diagnostic significance and therapeutic potential could also address the setting up of 
novel treatments in diseases where no cure is available to date. 
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INTRODUCTION 
Neurodegenerative disorders, in particular Alzheimer’s disease (AD) and Parkinson’s disease (PD), are 
increasing to epidemic proportions and, although the efforts carried out in the last decade by scientific 
community revealed important insights into their molecular bases, their etiology remains elusive. This 
condition reflects the high complexity of human brain biology. Since the great difference in cognitive 
abilities between humans and invertebrates is not correlated to a correspondent difference in the number 
of protein coding genes, it is more and more evident that additional mechanisms regulating alternative 
splicing and gene expression both at transcriptional and post-transcriptional levels play an important role in 
the development and function of the central nervous system (CNS) [1]. The fundamental role of non-coding 
RNAs (ncRNAs) in the fine regulation of gene expression in CNS, via control of nuclear processing of primary 
transcripts, transport of mature mRNAs to specific cellular compartments, as well as regulation of mRNA 
stability, translation and turnover, has become increasingly evident. The regulatory function of different 
classes of ncRNAs, such as microRNAs (miRNAs), piwi-interacting RNAs (piRNAs) and, more recently, long-
non coding RNAs (lncRNAs), has been documented in a broad range of biological processes, including cell 
proliferation, differentiation, apoptosis, development and immune responses [2-4]. 
While the small ncRNAs have been widely characterized in the last decade as important players in CNS 
development and functioning and have also been associated to a variety of neurodegenerative diseases [5; 
6], the specific functions of the lncRNAs, which have been primarily studied in the context of genomic 
imprinting, cancer, and cell differentiation, are only recently emerging as pivotal in CNS development and 
maintenance [7; 8].  
A possible pathogenetic role of lncRNAs in neurodegenerative diseases has been suggested by the growing 
number of identified lncRNAs shown to regulate expression of genes involved in the neurodegeneration 
process or already associated to neurodegenerative disorders. We here report on the functions of lncRNAs 
and their implication in neurodegenerative diseases, considering their dysregulation as a yet poorly 
explored pathogenetic mechanism implicated in the neurodegenerative process. Furthermore, the 
evaluation of their diagnostic significance and therapeutic potential will be discussed, helping to address 
one of the major challenges in neurobiology, the setting-up of a treatment in diseases where no cure is 
available to date. 
THE lncRNA BIOLOGY 
LncRNAs are defined as RNA molecules longer than 200 nucleotides, generally lacking a protein-coding 
function [9] and, unlike miRNAs or piRNAs, they are quite heterogeneous, differing in size, interacting 
partners and mode of action. The estimated number of the human lncRNA genes, reported in the current 
release of NONCODE Ev4 ID (http://www.noncode.org/analysis.php), is 90.062, a number significantly 
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higher than that of coding genes, now amounted to 19.815, according to the current GENCODE version 24 
release (http://www.gencodegenes.org/stats/current.html). Localization of lncRNAs is mainly nuclear, but 
they can also shuttle in the cytoplasm. Although the signals driving cytoplasmic localization are at now 
unknown [10-12], an RNA motif consisting of the pentamer sequence AGCCC has been recently reported to 
mediate the nuclear localization of BORG lncRNA [13]. LncRNAs can be broadly classified into two large 
categories, based on their position in respect to protein-coding genes: 1) intergenic lncRNAs, including 
pseudogenes, long intergenic non-coding RNAs (lincRNAs), and very long intergenic non-coding RNAs 
(vlincRNAs/macroRNAs); 2) coding gene-overlapping lncRNAs, represented by intronic lncRNAs, natural 
antisense transcripts (NATs), expressed non-coding regions (ENORs), enhancer RNAs (eRNAs), and 
promoter-associated long RNAs (PALRs) [14].  
The IncRNA gene structure is similar to that of protein-coding genes, but IncRNAs show a bias for having 
just one intron and a trend for less efficient co-transcriptional splicing [15; 16]. A proposed mechanism of 
lncRNA evolution is gene duplication followed by different events leading to non-coding genes that express 
transcripts endowed with regulatory functions [17]. On the basis of mass spectrometry data reported by 
Banfai and Derrien, a small fraction (8%) of the previously annotated lncRNAs was found to produce 
detectable peptides  [15; 18]. IncRNAs seem to have low translational potential even when ribosomes 
attempt to decode them. Given that for a number of predicted human protein coding genes no protein 
experimental data have been provided, we can hypothesize that some human putative lncRNA genes might 
fall in the group of genes encoding the missing human proteins, estimated to be about 18% of the human 
proteome (neXtProt release 19/9/2014). The few previously annotated lncRNA genes expressing transcripts 
undergoing translation encode small peptides (<100 aminoacids), whose biological significance is mostly 
unknown [19; 20].  
The expression of lncRNAs loci show similar features of protein-coding genes: transcription is mainly carried 
out by RNA polymerase II, splicing occurs using the same consensus signals of coding genes and half of the 
lncRNAs are 5’ capped and 3’ polyadenylated. It has been also shown that several lncRNAs may be spliced 
at their 5’ and 3’ ends generating circular RNAs. However the functional significance of circularization, 
possibly increasing their stability, has not been yet assessed [21]. Some lncRNAs are known to be 
transcribed also by RNA polymerase III, but these events cannot be detected using the current whole 
transcriptome sequencing methods which are based on the enrichment of poly(A)-purified transcripts [22]. 
This might be a reason why the number of lncRNAs is expected to be higher than that currently estimated. 
Nevertheless, lncRNAs are on average expressed at a lower level than mRNAs, although variations may 
occur in the different classes [11; 12] and their expression shows a cell-type specificity higher than that of 
protein coding genes [23]. LncRNA gene expression is believed to be regulated by mechanisms similar to 
those of protein-coding genes, including control of their synthesis by transcription factors and histone 
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modifications, and RNA splicing, but this area of lncRNA biology still remains quite unexplored [24-26]. A 
recent study, integrating ChIP-seq, RNA-seq and based-BRIC-seq RNA half-life data, highlighted how 
regulation of RNA degradation plays an important role in determining transcript levels of many genes [27]. 
Similarly, the stability of lncRNAs might have in some cases an important role in their modulation with a 
consequent effect of lncRNAs post-transcriptional regulatory function [28].  LncRNAs have similar half-life 
pattern of mRNAs [29]: lncRNAs with short half-lives (< 4 h) have generally a regulatory function, whereas 
lncRNAs with long half-lives (≥ 4 h) are involved in housekeeping roles [30]. The stability of lncRNAs seems 
to be associated with their physiological roles, but this issue was not sufficiently investigated, even if recent 
studies provided findings addressing the relationship between lncRNA stability and their biological function 
in specific pathways [31; 32]. The molecular mechanisms regulating lncRNA stability are not well known; 
the specific RNA decay elements usually located in the 3’UTR of mRNAs, including AU-rich elements (AREs) 
and Puf family protein-binding sites, were not demonstrated to have a role in lncRNA stability, even if a 
possible function of predicted AREs should be further investigated [28]. 
Although IncRNAs selective pressure is between the highest one of coding genes and that of the ancestral 
repeat sequences, which is considered to be under neutral selection, the promoters of IncRNAs are under 
very high selective pressure, with levels comparable to the promoters of protein coding genes [15; 25; 33-
35]. 
Unlike miRNAs, they are not highly conserved and at now their sequence does not allow to identify 
consensus sites and associated specific functions, even if high numbers of correlated positions among 
multiple IncRNA sequence alignments suggest that these regions are under selective pressure to maintain a 
functional RNA structure [15]. Consistently, mammalian and zebrafish IncRNAs show short stretches of 
conserved sequence, hence suggesting a functional relevance. Similarly, both location and structure of 
IncRNAs seem to be conserved, even in the absence of a high sequence conservation [23]. 
 
MECHANISMS OF ACTION OF lncRNAS 
LncRNAs, being a large fraction of noncoding transcripts, might represent an important source of molecular 
regulators in the eukaryotic nucleus, contributing to modulate gene expression at different levels. The role 
of lncRNAs in the fine tuning of gene expression may quickly respond to changes of environmental 
conditions or to gene silencing as part of a developmental program [23].  
In the last decade an increasing number of studies highlighted the involvement of lncRNAs at all levels of 
nuclear architecture consistent with DNA replication, transcriptional and post-transcriptional regulatory 
mechanisms and epigenetic functions. LncRNAs show also important cytoplasmic functions concerning 
positive and negative regulation of both mRNA and nascent protein stability, regulation of translation and 
miRNA activity [24].  
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An example of lncRNA involved in DNA replication and maintenance of telomere stability is TERRA, a 
transcript containing telomeric UUAGGG repeats able to sequester the single strand DNA-binding protein 
hnRNPA1 and essential for DNA replication [36; 37] (Figure 1 A). The lncRNA control of nuclear architecture 
and transcription depends on different biological mechanisms. One of these is the long range DNA looping 
formation [38], promoting inter-or trans-chromosomal interactions to bring together enhancer/promoter 
pairs, or different promoters separated by large stretches on the same chromosome, or on different 
chromosomes [39] (Figure 1 B). Nuclear lncRNAs, interacting with chromatin and chromatin modification 
complexes or regulating gene expression, generally show low stability, allowing a dynamic gene expression 
control in response to environmental signals [28]. Furthermore, some of the nuclear sub-compartments are 
assembled on lncRNAs, such as the nuclear-enriched abundant transcript 1 (NEAT1). NEAT1 has been 
shown to scaffold nuclear paraspeckles, mammalian-specific ribonucleoprotein bodies regulating mRNA 
splicing and maturation, through RNA sequestering [40; 41] (Figure 1 C). lncRNAs belonging to NAT 
subclass, unlike proteins, can also act in cis or trans to guide epigenetic modifier complexes to targeted 
sites, by pairing with DNA or mRNA sequences (Figure 1 D). The cis function consists in the recruitment of 
protein complexes to their site of transcription, conversely the trans activity leads to the formation of 
protein complexes by binding and sequestering transcription factors away from their targeted 
chromosomal regions which are their site of transcription [42].  
The lncRNAs transcription can generate a molecular structure that may lead the formation or remodeling of 
nuclear domains, through the recruitment or sequestration of proteins already present in the nuclear 
compartment, influencing their interactions [43]. These interchromatin granules are often characterized by 
specific functions such as pre-mRNA splicing and maturation. Unlike cellular organelles, these domains are 
not membrane delimited, but they are characterized by the specific interactors forming them in a stable 
fashion, maintaining the components associated (Figure 1 E). They often form close to the sites of RNA 
components involved in transcription, thus functioning as molecular anchors [44]. A well known lncRNA-
mediated biological event concerning transcription regulation and based on nuclear architecture 
modification is X chromosome-inactivation (Figure 1 F) as well as the imprinting activity of lncRNAs and 
their role in the fine regulation of epigenetic modifications [24]. By means of lncRNA regulatory function, 
the transcriptional status of an entire chromosome can be controlled in a regional-, locus- or even allele-
specific manner, through the recruitment of chromatin modifiers to the site of transcription. These 
complexes can create a local chromatin environment that may promote or inhibit the assembling of other 
regulators [45].  
At cytoplasmic level the lncRNAs can control mRNA and protein stability, as well as mRNA transport and 
localization (Figures 1 G and H). The activity of TINCR (terminal differentiation-induced ncRNA) is an 
example of a lncRNA involved in post-transcriptional regulatory mechanims. TINCR is required during 
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epidermal differentiation for the induction of specific key mediators. It localizes in the cytoplasm and, 
through the interaction with Staufen 1 protein (STAU1), promotes the stability of mRNAs containing the 
TINCR box motif [2]. LncRNAs can also have a role in the regulation of translation through the binding of the 
sense mRNA and consequent impairment of ribosome entry or arrest of translation between the initiation 
and elongation steps. In this context lincRNA-p21 was reported to interact with the DDX6 (DEAD box 
helicase 6) translational repressor in particular conditions, repressing the translation of its mRNA targets 
[46] (Figures 1 H). On the contrary, an instance of positive regulation of translation is provided by the 
antisense Uchl1 lncRNA (UCHL1-AS1), which has been shown to increase the UCHL1 protein level without 
leading to a change of the mRNA level [47]. UCHL1-AS1 overlaps the first 73 nucleotides of UCHL1 mRNA 
and contains two embedded repetitive sequences, one of which, SINEB2, is necessary for the induction of 
protein translation [47]. This repetitive sequence is present in many other lncRNAs from FANTOM3 
database, suggesting a potential role of these RNA species in positively regulating translation of target 
transcripts [48]. 
LncRNAs were demonstrated to interact also with miRNAs and their target sites thereby modulating miRNA 
activity [49]. Interestingly, a number of lncRNAs has been reported to act as miRNA sponges, reducing the 
molecules available to bind their mRNA targets [24]. These RNA cross-interactions suggest the presence in 
the cell of a ncRNA network where these molecules mutually regulate themselves by sequestering each 
other temporarily, or by degrading each other through dsRNA formation [21; 50] (Figure 1 I). 
The current knowledge on the lncRNAs mode of action shows how these RNA molecules play important 
roles at different levels of gene expression regulation, particularly when a fine tuning of a specific gene 
transcription is necessary to produce a fast response to stimuli of different origin. This regulatory function 
is consistent with mechanisms leading to a short lncRNA half-life and with a number of IncRNAs that 
currently seem to be higher than that of protein-coding genes (NONCODE Ev4 ID 
http://www.noncode.org/analysis.php), providing the nucleus with a very complex RNA-based system 
aimed at regulating coding-gene expression [15]. A regulatory mechanism based on an RNA-address code 
may act more rapidly and with a lower energy cost than a system based only on proteins [23]. In fact, 
lncRNAs do not need to be translated and/or transported into the cytoplasm and their targets are usually 
localized close to or overlapping with their own genomic loci. In contrast to the model of nuclear domains 
promoting molecular interactions, the spatial-based control can lead to the separation of the interactors 
until the appropriate moment. Environmental stresses may have as consequences the retention of specific 
proteins in the nucleolus, away from their normal site of action, thanks to the expression of specific 
noncoding RNAs [51]. According to the current knowledge on lncRNA functions, these RNA molecules are 
part of regulatory mechanisms for a fine control of gene expression able to respond to internal/external 
environmental changes, to manage complex biological events or developmental programs. 
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LncRNAs IN NEURODEGENERATIVE DISEASES 
Recent data highlight that lncRNAs are important in the development and functioning of the nervous 
system by both promoting the self-renewal of neural stem cells and neuronal differentiation, and by 
participating in the control of synaptic plasticity. Although a precise functional role in the nervous system 
has been attributed only to a few of them so far, lncRNAs have been described to be differentially 
expressed at specific stages during CNS development [52] or in specific cerebral regions [53].  
It is therefore not surprising that misregulation of lncRNAs might play a pathogenetic role in 
neurodegenerative diseases. This view has been reinforced by the identification of a growing number of 
lncRNAs that directly regulate the expression of genes associated to neurodegenerative disorders, including 
Alzheimer’s, Parkinson’s, Huntington’s diseases, Fragile X syndrome and Fragile X tremor/ataxia syndrome 
as well as spinocerebellar ataxia 7 or, by still unexplored mechanisms, the alternative splicing or mRNA 
transport/localization, as recently described in Frontotemporal dementia/Amyotrophic lateral sclerosis and 
spinocerebellar ataxia 8, respectively (Table 1).  
In the following paragraphs, we will describe the diverse mechanisms reported for lncRNAs in 
neurodegenerative diseases and discuss how they could mechanistically be involved in the 
neurodegenerative processes. 
 
Alzheimer Disease 
Alzheimer disease (AD) is the most common neurodegenerative disease affecting aged population and, 
etiologically, it is a complex disorder with the majority of cases occurring as sporadic ones and only 10% 
showing family history. Genes associated to familial forms are mainly implicated in the processing and 
maturation of the amyloid precursor protein (APP) into the cleaved Aβ peptides which can form 
extracellular deposits in affected brains, the senile plaques, when the more amyloidogenic Aβ42 peptide is 
generated. This process is highly dependent on the correct cleavage of APP by the γ and β secretase 
enzymes.  The antisense transcript of the β-secretase encoding gene BACE1 (BACE1-AS) was reported to 
increase the stability of BACE1 mRNA and to prevent binding of miRNA 485-5p, therefore positively 
regulating BACE1 protein content and promoting Aβ42 synthesis (Figure 2) [54]. Expression of BACE1-AS 
can be induced by different cell stressors, including treatment with Aβ42 itself, which suggests a feed-
forward mechanism in AD pathogenesis [55]. Interestingly, BACE1-AS expression is elevated in AD patients 
brains together with the RNA-binding protein HuD which can bind both BACE1 and BACE1-AS transcripts 
and increase their stability (Figure 2) [55; 56]. HuD can also bind and stabilize APP mRNA, thereby 
promoting Aβ42 peptide formation by increasing APP and BACE1 protein content as well as BACE1-AS 
lncRNA level [56]. This was observed both in cortical tissue from AD individuals and in transgenic mice over-
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expressing HuD protein. As a therapeutic approach, modulation of BACE1 and BACE1-AS transcripts in APP 
transgenic mice by transient in vivo silencing was effective in reducing Aβ aggregation [57]. This potential 
therapeutic strategy targeting BACE1 and BACE1-AS was also confirmed in a human neuroblastoma disease 
cell model where gene-silencing of BACE1-AS decreased the BACE1-dependent cleavage of APP with a 
consequent reduction of senile plaque formation [58]. 
A recent genome-wide search for differentially expressed lncRNAs in post-mortem human AD brains 
revealed a specific disease-associated signature with both up-regulated and down-regulated lncRNAs, 
mainly representing intergenic lncRNAs [59]. Although the mode of action of such deregulated lncRNAs is 
mainly unknown so far, it will be interesting to test whether such lncRNAs may serve as disease-specific 
biomarkers for AD. The expression of three specific lncRNAs, 17A, NDM29 and 51A was reported to be 
upregulated in AD affected brains compared to healthy control brain tissues [60-62]. The lncnRNA 17A, 
embedded in an antisense orientation in the third intron of the human G-protein-coupled receptor 51 
(GPR51, also known as GABBR2) gene, was demonstrated to regulate GPR51/GABBR2 pre-mRNA processing 
and favour the generation of the alternative and unfunctional splicing isoform B of the GABA B receptor 
(GABAB R2) (Figure 2) [60]. Indeed, the stable expression of 17A in human neuroblastoma cells was shown 
to increase the synthesis of the GABAB R2 splicing isoform B that is defective of the intramembrane 
sequence peptide, thus generating non functional receptors unable to transduce GABAB-dependent 
intracellular signalling. In association to increased levels of the lncRNA 17A and to a defective GABAB 
signaling, the secretion of the Aβ peptide was found to be induced with an increase in the Aβ42/Αβ40 ratio 
[60]. Similarly, the up-regulation of the lncRNA NDM29 promoted Aβ secretion with an unbalance in the 
Aβ42/Αβ40 peptide ratio (Figure 2) [61]. Also the antisense ncRNA 51A, deriving from the first intron of 
SORL1 gene, a well recognized risk factor for AD, was described to promote the alternative splicing of 
SORL1 and to increase Aβ formation [62]. Interestingly, both 17A and NDM29 ncRNA expression can be 
induced by inflammatory stimuli, which represent a pathogenic mechanism in AD, with the possibility of 
modulating such effect on Aβ synthesis by using anti-inflammatory drugs [60; 61].   
The expression of the lncRNA BC200/BCYRN1 (the human orthologue of BC1), which acts as a negative 
regulator of local protein synthesis at synapses, was reported to be altered in AD patients with opposite 
results, showing both down-regulation [63] and up-regulation [64] in affected brains. Despite this 
discrepancy in their observations, which probably reflects the different specific brain areas analyzed by the 
Authors, BC200 is able to interact with different RNA-binding proteins known to control mRNA translation, 
including FMRP, PABP1 and SYNCRIP proteins, in post-synaptic dendritic microdomains (Figure 2) [65-67].  
 
Frontotemporal dementia and amyotrophic lateral sclerosis 
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Frontotemporal dementia (FTD) is the second important cause of dementia after AD in elderly population 
and, contrarily to the latter, it affects mainly the frontal and temporal lobes of the brain. Clinically, three 
different FTD subtypes can be distinguished: behavioral variant FTD, semantic dementia and progressive 
non-fluent aphasia, each accompanied by specific clinical features. FTD is a hereditary condition in nearly 
40% of cases and several causative genes are associated to the disease, including MAPT, PGRN, C9ORF72 
and VCP. In the last few years increasing neuropathological and genetic findings have further supported the 
clinical observations of a disease continuum with motor neuron disease, in particular with amyotrophic 
lateral sclerosis (ALS). Neuropathological data, in fact, sustain the presence of abnormal cytoplasmic 
inclusions of the RNA-binding protein (RBP) TDP-43 in affected tissues of a subset of FTD patients (45%; 
FTD-TDP) and of nearly all ALS patients. Similarly, another nuclear RBP, FUS/TLS, forms cytoplasmic 
aggregates in affected tissues of 9% of FTD patients (FTD-FUS) and in familial ALS forms with mutations in 
FUS/TLS gene (~5%). Genetically, the pathological expansion of the hexanucleotide GGGGCC repeat in the 
first intron of C9ORF72 gene represents the most frequent cause of both familial and sporadic FTD and ALS 
cases. 
The lncRNAs NEAT1_2 and MALAT1 (NEAT2) were recently identified as RNA targets of TDP-43 by different 
binding assays both in experimental models and in human brains [68; 69]. NEAT1_2 is essential for 
paraspeckle assembly [40], whereas MALAT1 localizes at distinct nuclear sub-domains, the speckles, in 
association to different splicing factors [70]. Interestingly, binding of TDP-43 to these two lncRNAs was 
reported to be increased in human FTD brains compared to healthy controls [69]. Also FUS/TLS was shown 
to bind to NEAT1_2 lncRNA although at a distinct site compared to TDP-43 and to associate to a consistent 
fraction (30%; 71/234) of all literature annotated lncRNAs [71]. Both TDP-43 and FUS co-localize with the 
lncRNA NEAT1_2 in the nuclear paraspeckles in experimental cell lines, but NEAT1_2 expression and 
localization in paraspeckels are increased in spinal motoneurons of sporadic ALS patients at early stages of 
disease [69]. Moreover, FUS loss-of-function was shown to impair paraspeckle assembly in disease cell 
models, while FUS-positive aggregates in the cytoplasm associated to FUS mutations induced sequestration 
of paraspeckle proteins [72].  
In a different context, the RBP FUS/TLS was also described to interact with a series of lncRNAs transcribed 
from the 5’ region of CCND1 (Cyclin D1) gene in response to experimentally induced DNA damage [73]. 
Such lncRNAs-RBP binding determines a specific conformational change of FUS/TLS protein, making it able 
to bind to the histone acetyltransferases CBP and p300 and, as a consequence, to inhibit their activities as 
transcriptional co-activators [73]. 
Therefore in FTD and ALS diseases where the activity of TDP-43 and FUS is impaired affecting RNA 
metabolism at different levels, also the interaction of these two RBPs with lncRNAs may be defective, 
representing a novel pathogenetic mechanism to be explored. 
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Parkinson disease 
Parkinson disease (PD) is mainly a movement disorder, often accompanied by sensory and
 
cognitive deficits 
or sleep problems, and is characterized by the specific neurodegeneration of the dopaminergic neurons in 
the substantia nigra. Similarly to AD and ALS, only a minor proportion of cases (5-10%) is familial with a 
wide genetic heterogeneity in both dominant and recessive disease forms. Several causative genes, 
including Parkin, DJ-1 and PINK1, strongly support mitochondria dysfunction as one important pathogenetic 
mechanism in PD. PINK1 (PTEN-induced putative kinase 1) is involved in multiple aspects of mitochondria 
quality control and acts as a sensor of damaged mitochondria. By accumulating on the outer membrane of 
depolarized mitochondria, PINK1 is able to recruit also Parkin ubiquitin ligase on damaged mitochondria 
and to target them to degradation through autophagy. In line with a view of regulatory networks 
controlling target mRNA and protein content through epigenetic mechanisms, an antisense transcript of 
PINK1 gene (PINK1-AS) was described to have a regulatory function on a short PINK1 splicing isoform 
(svPINK1) encoding for the C-terminal region of the PINK1 protein with kinase activity [74]. The ncRNA 
PINK1-AS specifically and positively regulates the stability of the svPINK1 transcript, although it is not clear 
yet the role of this short PINK1 protein isoform and its relevance in PD pathogenesis.  
Also the antisense transcript of UCHL1 (ubiquitin carboxy-terminal hydrolase L1), UCHL1-AS1, which is 
associated to PD both as a risk factor and as a rare causative gene, was recently identified in mice to exert 
its regulatory function on its target Uchl1 mRNA at translational level [47]. UCHL1 protein is specifically 
expressed in the brain and in dopaminergic neurons where it is involved in the ubiquitin-proteasome 
system (UPS) by acting both in tagging proteins for degradation and in recycling ubiquitin molecules from 
degraded proteins. The lncRNA AS-Uchl1 is mainly localized in the nucleus but, upon rapamycin treatment 
which inhibits mTOR pathway and CAP-dependent translation, it is induced to translocate into the 
cytoplasm. As a consequence, an increased association of its target Uchl1 transcript to heavier polysomes 
and an increased translation of the UCHL1 protein are observed as strictly dependent on AS-Uchl1 binding 
to its sense Uchl1 mRNA [47]. It is interesting to note that the ability of the lncRNA AS-Uchl1 to positively 
regulate translation of its sense transcript is due to the presence of the SINEB2 repetitive element [47; 48]. 
A recent RNA-seq approach in leukocytes and brain tissues from PD patients and controls revealed 
deregulation of specific lncRNAs, including the U1 spliceosomal lncRNA which was commonly up-regulated 
in PD blood and brain [75], suggesting its potential use as a disease biomarker. 
 
Huntington’s disease 
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Huntington’s disease (HD) is an autosomal dominant progressive neurodegenerative disorder caused by a 
CAG trinucleotide repeat expansion in exon 1 of huntingtin (HTT) gene, which generates a mutant 
huntingtin protein with an expanded polyglutamine tract at the N-terminus and potential toxic effects [76]. 
A natural antisense transcript, HTT-AS, was identified at the Huntington’s disease repeat locus. The HTT-AS 
gene contains three exons and gives rise to two alternatively spliced isoforms: HTT-AS_v1, which is 
composed by exons 1 and 3 and includes the CAG repeat, and HTT-AS_v2, containing only exons 2 and 3. It 
was shown that the repeat expansion reduces HTT-AS_v1 expression and, consistently, the levels of HTT-
AS_v1 are reduced in human HD frontal cortex. Moreover, HTT-AS_v1 is able to negatively regulate HTT 
expression in a repeat length-dependent manner [77]. 
A role of BDNF-AS, a lncRNA transcribed starting from the brain derived neutrophic factor (BDNF) opposite 
strand, in the development of HD was also suggested. BDNF levels are known to be strongly downregulated 
in the brains of HD patients, possibly contributing to the clinical manifestations of the disease [78]. It was 
recently shown that BDNF-AS knock-down is able to induce BDNF upregulation [79]. In addition, BDNF-AS 
was demonstrated to inhibit BDNF transcription by recruiting the EZH2 catalitic subunit of the PRC2 
silencing complex to the BDNF promoter, with consequent methylation of Lys27 of histone H3 
(H3K27me2/3) [80; 81]. This evidence suggests a potential role of BDNF-AS dysregulation in HD 
pathogenesis. 
Another lncRNA potentially involved in HD is ABHD11-AS1. The mouse ortholog, named Abhd11os, is 
enriched in the striatum and its expression levels are markedly reduced in different mouse models of HD. 
Interestingly, Abhd11os overexpression is neuroprotective against an N-terminal fragment of the mutant 
huntingtin, whereas Abhd11os knockdown is protoxic, indicating that the loss Abhd11os likely contributes 
to striatal vulnerability in HD [82].  
Many other lncRNAs have been found to be dysregulated in HD a d might play a significant role in HD 
neurodegeneration. Among them, the neural human accelerated region 1 (HAR1) lncRNA was shown to be 
repressed by REST (which is aberrantly localized to the nucleus in HD neurons) and to display significantly 
lower levels in the striatum of HD patients [83]. Another lncRNA found to be deregulated in HD is the TUNA 
(Tcl1 upstream neuron associated) lincRNA, which is involved in pluripotency and neural differentiation of 
embryonic stem cells. The expression of TUNA in the striatum of HD patients was found to be associated 
with pathological disease severity, decreasing significantly as the disease grade increased [84]. Moreover, 
the analysis of microarray data revealed that TUG1, LINC000341, RPS20P22, NEAT1 lncRNAs are 
upregulated in HD brains, while MEG3, DGCR5, LINC000342 are downregulated [85]. It is worth noting that 
among these genes there are REST and p53 targets, and some of them are also known to interact with the 
PRC2 complex. Interestingly, the NEAT1 lncRNA was also proposed to be involved in ALS pathogenesis (see 
above).  
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Fragile X syndrome and Fragile X tremor/ataxia syndrome 
Fragile X syndrome (FXS) is a genetic neurodevelopmental disorder characterized by moderate to severe 
intellectual deficit, macroorchidism and distinct physical features, which is caused by the expansion beyond 
200 repeats of a CGG trinucleotide repeat in the 5’-untranslated region (5’-UTR) of the Fragile X mental 
retardation 1 (FMR1) gene [86]. This repeat expansion, called ‘full mutation’, causes FMR1 upstream region 
to be abnormally methylated, resulting in FMR1 transcriptional silencing and decreased protein levels in the 
brain. Fragile X tremor/ataxia syndrome (FXTAS) is a neurodegenerative disease whose pathogenesis is 
distinct from that of fragile X syndrome. FXTAS is caused by the expansion of the same CGG repeat in the 
FMR1 gene, but, differently from FXS, the expanded repeat ranges from 55 to 200 units in size (the so-
called 'premutation'), resulting in a toxic gain-of-function of FMR1 RNA [87]. 
Different lncRNAs were recently discovered at the FMR1 locus which display altered expression in FXS and 
FXTAS. FMR1-AS1 (FMR1 antisense RNA 1), also known as ASFMR1 or FMR4, is a primate-specific lncRNA 
overlapping the CGG repeat region, sharing the promoter with FMR1 and transcribed in the opposite 
direction [88; 89]. The repeat expansion seems to affect transcription in both directions as, similarly to 
FMR1, the expression of FMR1-AS1 was also found to be upregulated in FXTAS patients carrying the 
premutation and silenced in full mutated FXS patients. Interestingly, the FMR1-AS1 premutated transcript 
exhibits a specific splicing isoform which is absent in the case of normal or full mutated alleles [88]. FMR1-
AS1 was not shown to have a regulatory activity on FMR1 expression, but FMR1-AS1 knockdown enhanced 
apoptosis while its overexpression increased cell proliferation, suggesting an anti-apoptotic function and a 
possible role in protection of neurons from death [89]. Furthermore, in differentiating human neural 
precursor cells (hNPCs), FMR1-AS1 expression is developmentally regulated in opposition to expression of 
both FMR1 and MBD4 (methyl-CpG-binding domain protein 4), a FMR1-AS1-responsive gene, indicating a 
likely gene-regulatory function of this lncRNA during normal development [90]. Very recently, FMR1-AS1 
was also found to be a chromatin-associated transcript and it was shown to alter the chromatin state and 
the expression of several hundred genes in trans. Among these genes, there was an enrichment for those 
involved in neural development and cellular proliferation. Indeed, it was further demonstrated that FMR1-
AS1 may promote cellular proliferation of hNPCs [91]. It was also proposed that altered FMR1-AS1 
expression might contribute to some clinical aspects of FXS/FXTAS [89].  
In addition, Pastori and colleagues [92] identified two further lncRNAs mapping to the FMR1 locus: FMR5 
and FMR6. FMR5 is a sense transcript localized upstream of the FMR1 promoter and found to be expressed 
at low levels in both FXS/FXTAS patients and healthy individuals’ brains, without significantly differences 
between full mutation, premutation and control samples. FMR6 is an antisense transcript overlapping the 
3’ region of FMR1, which is specifically silenced in both FXS and FXTAS patients. Since these two lncRNAs 
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were expressed in peripheral blood leukocytes, they were proposed as useful biomarkers for FXS/FXTAS 
early detection and therapeutic intervention [92]. 
 
Spinocerebellar ataxia 
Spinocerebellar ataxias (SCAs) are a complex group of clinically and genetically heterogeneous 
neurodegenerative diseases characterized by progressive cerebellar ataxia in association with a broad 
spectrum of neurological and other clinical conditions. 
Spinocerebellar ataxia type 8 (SCA8), a slowly progressive ataxia, is caused by an expanded CTG/CAG 
trinucleotide repeat (usually 80-250 units) on chromosome 13q21. Two genes transcribed in opposite 
directions encompass the repeat: ataxin 8 (ATXN8), encoding a polyglutamine protein in the CAG direction, 
and ataxin 8 opposite strand (ATXN8OS), whose transcription produces a noncoding RNA with a CUG 
expansion [93]. The ATXN8OS lncRNA containing the CUG repeat expansion was demonstrated to 
accumulate in ribonuclear inclusions along with the RBP MBNL1, and to cause splicing changes and 
increased expression of the GABA-A transporter 4 (GAT4/Gabt4), suggesting the involvement of toxic gain-
of-function effects of the expanded-repeat ATXN8OS transcript in SCA8 pathogenesis [94]. Moreover, it was 
shown that the expression of human ATXN8OS in Drosophila induces late-onset neurodegeneration of the 
retina [95]. This effect was seen following the overexpression of both the wild-type and the repeat-
expanded lncRNA, but it was proposed that the CUG expansion could alter the binding of ATXN8OS to RBPs. 
In particular, ATXN8OS was demonstrated to interact with Staufen, an RBP conserved in Drosophila and 
humans that mediates mRNA localization and transport in the nervous system. It is interesting to note that 
the ATXN8OS binding domain maps to the region which is expanded in SCA8 patients, suggesting that the 
interaction with Staufen could be compromised by the CUG repeat expansion, leading to disease [95]. 
Spinocerebellar ataxia type 7 (SCA7) is a neurodegenerative disorder due to a CAG 
trinucleotide/polyglutamine repeat expansion (usually 36 or more repeats) in the ataxin 7 (ATXN7) gene 
[96]. Larger CAG-repeat expansions are associated with an earlier disease onset and a more severe disease 
progress. A lncRNA, SCAANT1 (SCA7/ATXN7 antisense RNA 1), was identified in the ataxin-7 promoter 
region which is transcribed antisense to the ATXN7 gene starting from an alternative promoter. Loss of 
SCAANT1 was shown to derepress ataxin-7 sense transcription from the alternative promoter and was 
accompanied by chromatin remodeling. On the contrary, upregulation in cis of SCAANT1 transcription 
caused down-modulation of ATXN7 and was accompanied by post-translational modification of histones 
[97]. These data demonstrated the involvement of the SCAANT1 antisense lncRNA in the regulation of 
ATXN7 expression, also indicating a likely contribution of lncRNA-mediated altered epigenetic regulation to 
SCA7 disease pathogenesis. Another lncRNA, ATXN7L3B (also known as lnc-SCA7), was shown to interact 
directly with ATXN7 mRNA. The nature of this interaction is likely to be regulatory, since mutations in 
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ATXN7 disrupt the interaction and result in a neuron-specific increase in ATXN7 expression, predominantly 
in the SCA7 disease-relevant tissues, the retina and cerebellum, contributing to the selective 
neurodegeneration observed in SCA7  [98]. 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
The role of lncRNAs in the pathogenesis of neurodegenerative disorders is only beginning to be explored, 
but promises to open a new scenario for the setting up of innovative therapies for diseases for which no 
effective cure is available.  
The great variety of lncRNA mechanisms of action and the relatively limited number of studies on lncRNAs 
in specific neurodegenerative diseases make it difficult to assemble a precise and conclusive picture of their 
involvement in these disorders. This notwithstanding, some recurrent pathomechanisms are clearly 
emerging from the literature data. Among them, the most straightforward is the dysregulation of lncRNAs 
which can in turn affect the expression of genes involved in the neurodegenerative process (e.g. BACE1), 
acting at different levels (chromatin structure, transcription, mRNA stability, translational efficiency, miRNA 
binding). This is usually the case, for instance, of many antisense transcripts transcribed from the same 
locus of the sense gene. Another group of lncRNAs deserving particular attention is composed by those 
lncRNAs which are able to interact with components of the epigenetic machinery, since their deregulation 
potentially alters the chromatin state and the expression of several genes, affecting multiple pathways 
involved in neurodegeneration. Another property of lncRNAs which can be relevant in triggering the 
neurodegenerative events is their ability to interact with RNA-binding proteins (RBPs) because, again, their 
dysregulation may impact the processing, stability, translation and localization of many different target 
transcripts. In some cases, the accumulation of a given lncRNA may have a toxic effect, as in the case of 
repeat expansion diseases. In other cases, our knowledge is limited to an evidence of lncRNA expression 
changes in the brains of affected patients compared to the healthy individuals and functional studies aimed 
at shedding light on their involvement in the neurodegenerative diseases are missing. 
The elucidation of the lncRNA-mediated mechanisms of action is fundamental to better understand their 
role in brain functioning and their implication in the occurrence of neurodegenerative conditions. For this 
purpose, an effective strategy will be to study the effect of knocking-out or knocking-down specific lncRNAs 
in suitable model organisms and cell lines. Moreover, reports on the role of lncRNAs in cancers and 
malignant diseases of the CNS such as glioblastoma which are both numerous, and age-related and 
neurodegenerative in nature [8], may help shed light on the mechanisms of lncRNAs in neurodegenerative 
diseases. The latest transcriptome sequencing technologies, along with the development of suitable 
bioinformatic tools for identifying new potentially functional lncRNAs, will allow to expand the repertoire of 
known lncRNAs and to identify those which are dysregulated during the neurodegenerative processes. In 
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addition, as our knowledge on the role of lncRNAs in the neurodegenerative disorders progresses, other 
evidence of dysregulated lncRNAs shared by different pathologies could also emerge, as in the case of 
NEAT1, uncovering common lncRNA-mediated pathomechanisms. 
Importantly, the identification of lncRNA expression profiles robustly associated to the disease condition 
will prompt the use of lncRNAs as diagnostic and predictive biomarkers, especially if abnormal lncRNA 
expression patterns can be detected in blood and/or CSF of patients. In support of this perspective, the use 
of lncRNAs as diagnostic and prognostic markers is already successfully exploited in the field of oncology 
[8]. Moreover, a deeper understanding of the role of lncRNAs in neurodegenerative disorders will 
ultimately enable the development of innovative therapeutic strategies with lncRNAs as drug targets. A 
potential therapeutic intervention based on the reduction of the UBE3A antisense transcript (UBE3A-ATS) 
lncRNA using antisense oligonucleotides has been recently proposed for the treatment of patients affected 
by Angelman syndrome [99] and analogous oligonucleotide-mediated therapeutic strategies are also being 
developed by biotechnology companies for a wide range of disorders. Therefore we are confident that the 
experience gained in the above clinical fields will have also promising applications in the area of 
neurodegenerative diseases. In example, the targeted down-regulation of BACE1-AS, 17A, NDM29 and 51A 
lncRNAs by specific antisense oligonucleotides could represent a potential therapeutic approach to reduce 
Aβ production in Alzheimer’s disease as it already was shown to be effective in AD animal and cell models 
[57; 58; 60; 61]. Another conceivable strategy may consist in the pharmacological modulation of lncRNAs to 
modify consequently the expression of known target genes involved in neurodegeneration. 
In conclusion, lncRNAs can be considered a great promise for one of the major challenges of the last 
decades, early diagnosis and cure of neurodegenerative diseases that are having an increasing social impact 
with the lengthening of human lifespan. 
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FIGURE LEGENDS 
Figure 1: Regulatory mechanisms mediated by lncRNAs in the nucleus and in the cytoplasm 
Nuclear functions of lncRNAs: A. The lncRNA TERRA maintains telomere stability during DNA replication; B. 
lncRNAs promote inter- or trans-chromosomal interactions regulating transcription of target loci; C. 
lncRNAs are able to scaffold nuclear paraspeckles, participating in the regulation of mRNA splicing and 
maturation; D. lncRNAs can also act in cis or trans to guide epigenetic modifier complexes to targeted sites, 
by pairing with DNA or mRNA sequences; E. lncRNAs can generate inter-chromatin granules involved in pre-
mRNA splicing and maturation; F. lncRNAs have a role in X-chromosome inactivation by nuclear 
architecture modification. Cytoplasmatic functions of lncRNAs: G. lncRNAs can positively or negatively 
regulate target mRNA stability; H. lncRNAs can regulate protein levels by controlling their translation and 
stability; I. lncRNAs can interact with miRNAs acting as molecular sponge to modulate their activity . 
 
 
Figure 2: Dysregulated lncRNAs and affected pathways in the pathogenesis of Alzheimer’s disease. The 
BACE1-AS transcript increases the stability of BACE1 mRNA and prevents the binding of miR-485-5p, 
positively regulating BACE1 and promoting Aβ42 formation. BACE1-AS expression levels are elevated in AD 
and can be induced by Aβ42 itself, creating a feed-forward mechanism. Moreover, the RNA-binding protein 
HuD can bind both BACE1 and BACE1-AS transcripts, increasing their stability. The lncnRNA 17A, which is 
embedded in an antisense orientation within the GABBR2 gene, is upregulated in AD and favours the 
synthesis of the GABBR2 receptor splicing isoform B that is defective in transducing the GABAB-dependent 
intracellular signalling. The up-regulation of 17A, as well as of the lncRNA NDM29, promotes Aβ secretion 
with an increase in the Aβ42/Αβ40 peptide ratio. The antisense lncRNA 51A, located in the first intron of 
SORL1 gene, promotes the alternative splicing of SORL1 and increases Aβ formation. Finally, the expression 
of the lncRNA BC200, which acts as a regulator of local protein synthesis at synapses, can be both down- or 
up-regulated in AD brains. BC200 is able to interact with different RNA-binding proteins known to control 
mRNA translation in post-synaptic dendritic microdomains. The vertical arrows shown on the left of 
lncRNAs BACE1-AS, NDM29, 17A and BC200 indicate up- or down-regulation in AD. 
 
Aβ= amyloid-beta peptide; APP= amyloid precursor protein; BACE1= beta-site APP-cleaving enzyme 1; 
BACE1-AS= BACE1 antisense RNA; BC200= brain cytoplasmic RNA of 200 nucleotides; GABBR2= gamma-
aminobutyric acid (GABA) B receptor 2; HuD= Hu-antigen D/ELAV like protein 4; NDM29= neuroblastoma 
differentiation marker 29; RBPs= RNA-binding proteins; SORL1= sortilin-related receptor, L(DLR class) A 
repeats containing. 
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Figure 1: Regulatory mechanisms mediated by lncRNAs in the nucleus and in the cytoplasm  
Nuclear functions of lncRNAs: A. The lncRNA TERRA maintains telomere stability during DNA replication; B. 
lncRNAs promote inter- or trans-chromosomal interactions regulating transcription of target loci; C. lncRNAs 
are able to scaffold nuclear paraspeckles, participating in the regulation of mRNA splicing and maturation; D. 
lncRNAs can also act in cis or trans to guide epigenetic modifier complexes to targeted sites, by pairing with 
DNA or mRNA sequences; E. lncRNAs can generate inter-chromatin granules involved in pre-mRNA splicing 
and maturation; F. lncRNAs have a role in X-chromosome inactivation by nuclear architecture modification. 
Cytoplasmatic functions of lncRNAs: G. lncRNAs can positively or negatively regulate target mRNA stability; 
H. lncRNAs can regulate protein levels by controlling their translation and stability; I. lncRNAs can interact 
with miRNAs acting as molecular sponge to modulate their activity .  
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Figure 2: Dysregulated lncRNAs and affected pathways in the pathogenesis of Alzheimer’s disease. The 
BACE1-AS transcript increases the stability of BACE1 mRNA and prevents the binding of miR-485-5p, 
positively regulating BACE1 and promoting Aβ42 formation. BACE1-AS expression levels are elevated in AD 
and can be induced by Aβ42 itself, creating a feed-forward mechanism. Moreover, the RNA-binding protein 
HuD can bind both BACE1 and BACE1-AS transcripts, increasing their stability. The lncnRNA 17A, which is 
embedded in an antisense orientation within the GABBR2 gene, is upregulated in AD and favours the 
synthesis of the GABBR2 receptor splicing isoform B that is defective in transducing the GABAB-dependent 
intracellular signalling. The up-regulation of 17A, as well as of the lncRNA NDM29, promotes Aβ secretion 
with an increase in the Aβ42/Αβ40 peptide ratio. The antisense lncRNA 51A, located in the first intron of 
SORL1 gene, promotes the alternative splicing of SORL1 and increases Aβ formation. Finally, the expression 
of the lncRNA BC200, which acts as a regulator of local protein synthesis at synapses, can be both down- or 
up-regulated in AD brains. BC200 is able to interact with different RNA-binding proteins known to control 
mRNA translation in post-synaptic dendritic microdomains. The vertical arrows shown on the left of lncRNAs 
BACE1-AS, NDM29, 17A and BC200 indicate up- or down-regulation in AD.  
 
Aβ= amyloid-beta peptide; APP= amyloid precursor protein; BACE1= beta-site APP-cleaving enzyme 1; 
BACE1-AS= BACE1 antisense RNA; BC200= brain cytoplasmic RNA of 200 nucleotides; GABBR2= gamma-
aminobutyric acid (GABA) B receptor 2; HuD= Hu-antigen D/ELAV like protein 4; NDM29= neuroblastoma 
differentiation marker 29; RBPs= RNA-binding proteins; SORL1= sortilin-related receptor, L(DLR class) A 
repeats containing.  
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NDM29 Up 
induced by inflammatory processes 
  [60; 61] 
 
51A Up Promotes the alternative splicing of SORL1 and increases Aβ formation   [62] 
 
BC200/BCYRN1 Up/Down Regulates translation by interacting with RNA-binding proteins   [63; 64; 65-67] 
     
FTD/ALS NEAT1 Up (early stages of ALS) 
Role in paraspeckle assembly; binds to TDP-43 and FUS; increased 
binding to TDP-43 in FTD; expression and localization in paraspeckles 
increased in ALS motoneurons 
  [40; 68; 69; 71] 
 
MALAT1 - 
Recruits splicing factors to paraspeckles; regulates phosphorylation of 
splicing factors 
  [68; 70] 
     
Parkinsons's Disease PINK1-AS - Positively regulates the stability of svPINK1 transcript   [74] 
 
UCHL1-AS1 - Positively regulates UCHL1 mRNA translation   [47; 48] 
 
U1 spliceosomal 
lncRNA  
Up -   [75] 
     
Huntington's Disease HTT-AS Down Negatively regulates HTT expression   [77] 
 
BDNF-AS - 
Inhibits BDNF transcrption by recruitment of the PCR2 epigenetic 
silencing complex 
  [78-81] 
 
ABHD11-AS1 Down 
Its overexpression is neuroprotective against an N-terminal fragment of 
the mutant huntingtin; its knockdown is protoxic 
  [82] 
 
HAR1 Down -   [83] 
 
TUNA Down 
Involved in pluripotency and neural differentiation of embryonic stem 
cells; its expression in the striatum of HD patients decreases with the 
increasing of disease grade 
  [84] 
 
TUG Up Binds the PCR2 epigenetic silencing complex   [85] 
 
LINC000341 Up -   [85] 
 
RPS20P22 Up -   [85] 
 
NEAT1 Up -   [85] 
 
MEG3 Down Binds the PCR2 epigenetic silencing complex   [85] 
 
DGCR5 Down -   [85] 
 
LINC000342 Down -   [85] 
     
FXS/FXTAS FMR1-AS1 Down in FXS/Up in FXTAS Anti-apoptotic function   [88-91] 
 
FMR5 - -   [92] 
 
FMR6 Down in FXS/FXTAS -   [92] 
     
Spinocerebellar Ataxia ATXN8OS - 
RNA toxic gain-of-function effects; altered binding to RNA-binding 
proteins 
  [93-95] 
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